DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Boniva Injection (Ibandronate Sodium) - Drug Interactions, Contraindications, Overdosage, etc




Intravenous ibandronate (6 mg) did not interact with intravenous melphalan (10 mg/m2) or oral prednisolone (60 mg/m2). [See Clinical Pharmacology]


There was no interaction between oral 30 mg tamoxifen and intravenous 2 mg ibandronate.

[See Clinical Pharmacology]

Bone Imaging Agents

Bisphosphonates are known to interfere with the use of bone-imaging agents. Specific studies with BONIVA have not been performed.


No cases of overdose were reported in premarketing studies with BONIVA Injection. Overdosage with intravenous bisphosphonates may result in hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively.

Dialysis would not be beneficial unless it is administered within 2 hours following the overdose.


Boniva is contraindicated in patients with the following conditions:

  • Hypocalcemia [see Warnings and Precautions]
  • Known hypersensitivity to BONIVA Injection or to any of its excipients. Cases of anaphylaxis, including fatal events, have been reported. [see Warnings and Precautions, Adverse Reactions]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017